A Single Arm Phase 2 Study of Gemcitabine Plus Nab-Paclitaxel in Combination With Pegvorhyaluronidase Alfa (PVHA; PEGPH20) and Pembrolizumab as Front-line Treatment for Metastatic Pancreatic Adenocarcinoma

Status: Withdrawn prior to enrolment

Phase of Trial: Phase II

Latest Information Update: 04 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Gemcitabine (Primary) ; Hyaluronidase (Primary) ; Paclitaxel (Primary) ; Pembrolizumab (Primary)
Indications Adenocarcinoma; Pancreatic cancer; Pancreatic ductal carcinoma
Focus Therapeutic Use

Most Recent Events

06 Jan 2020 Status changed from not yet recruiting to withdrawn prior to enrolment.
30 Oct 2019 Planned initiation date changed from 1 Oct 2019 to 15 Nov 2019.
16 Aug 2019 Planned primary completion date changed from 31 Oct 2019 to 31 Dec 2019.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight